Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.

Ikaro BrederJessica Cunha BrederIsabella BonilhaDaniel B MunhozSheila T Kimura MedorimaDaniela C OliveiraHelison R do CarmoCamila MoreiraAnatol KontushFrancesca ZimettiIlaria ZanottiLuiz Sergio F CarvalhoWilson NadruzElza MuscelliThiago QuinagliaAndrei Carvalho Spositonull null

Published in: Therapeutic advances in chronic disease (2020)

ClinicalTrials.gov identifier: NCT03932721.

Keyphrases

type diabetes
phase iii
study protocol
cardiovascular disease
glycemic control
phase ii
clinical trial
randomized controlled trial
low density lipoprotein
open label
adipose tissue